Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 6 de 6
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Exp Dermatol ; 30(10): 1532-1545, 2021 10.
Artigo em Inglês | MEDLINE | ID: mdl-34293242

RESUMO

Atopic dermatitis (AD) is a common inflammatory dermatosis that has multiple contributing factors including genetic, immunologic and environmental. Staphylococcus aureus (SA) has long been associated with exacerbation of AD. SA produces many virulence factors that interact with the human skin and immune system. These superantigens and toxins have been shown to contribute to adhesion, inflammation and skin barrier destruction. Recent advances in genome sequencing techniques have led to a broadened understanding of the multiple ways SA interacts with the cutaneous environment in AD hosts. For example, temporal shifts in the microbiome, specifically in clonal complexes of SA, have been identified during AD flares and remission. Herein, we review mechanisms of interaction between the cutaneous microbiome and SA and highlight known differences in SA clonal complexes that contribute to AD pathogenesis. Detailed knowledge of the genetic strains of SA and cutaneous dysbiosis is becoming increasingly relevant in paving the way for microbiome-modulating and precision therapies for AD.


Assuntos
Dermatite Atópica/imunologia , Dermatite Atópica/microbiologia , Microbiota/imunologia , Infecções Estafilocócicas/microbiologia , Dermatite Atópica/terapia , Humanos , Infecções Estafilocócicas/imunologia , Infecções Estafilocócicas/terapia , Staphylococcus aureus , Simbiose , Fatores de Virulência
2.
Dermatol Online J ; 25(6)2019 Jun 15.
Artigo em Inglês | MEDLINE | ID: mdl-31329391

RESUMO

Skin reactions related to secukinumab are uncommon. Although the initial phase 3 studies of this medication reported infection and urticaria as adverse cutaneous events, other cases of unique adverse events have since been reported. We are presenting a patient who developed an exuberant hand and foot reaction after starting secukinumab.


Assuntos
Anticorpos Monoclonais Humanizados/efeitos adversos , Vesícula/patologia , Toxidermias/patologia , Dermatoses do Pé/patologia , Dermatoses da Mão/patologia , Adulto , Vesícula/induzido quimicamente , Dermatite Atópica/complicações , Toxidermias/etiologia , Feminino , Dermatoses do Pé/induzido quimicamente , Dermatoses da Mão/induzido quimicamente , Humanos , Psoríase/tratamento farmacológico
3.
Brain Behav Immun ; 68: 238-247, 2018 02.
Artigo em Inglês | MEDLINE | ID: mdl-29080684

RESUMO

Acute stress is a physiological response of an organism to adverse conditions, contributing to survival; however, persistence through time may lead to disease. Indeed, exacerbation of inflammatory conditions such as psoriasis has been reported to follow stressors in susceptible patients. Because chronic stress cannot ethically be elicited in patients under controlled laboratory conditions, we studied genetically modified mice that naturally develop psoriasiform dermatitis, and subjected them to an ethological chronic social contact stress paradigm. Although we found elevated pro-inflammatory neuropeptide production of substance P (SP), calcitonin-gene-related peptide (CGRP) and nerve-growth factor (NGF) mRNA in the dorsal root ganglia (DRG) as well as pro-inflammatory cytokines in response to the social stressor, stress paradoxically prevented the development of the skin lesions. This effect of stress could be reversed by the treatment with glucocorticoid (GC) receptor blockers, suggesting that it was mediated through the upregulation of corticosterone secretion. Extrapolating to humans, the worsening of disease in susceptible patients with psoriasis could be attributed to a defect in the Hypothalamic-Pituitary-Adrenal (HPA) axis with an impaired production of GC during situations of adversity, thus rendering them unable to counteract the pro-inflammatory effects of chronic stressors.


Assuntos
Psoríase/fisiopatologia , Estresse Psicológico/metabolismo , Corticosteroides/metabolismo , Animais , Peptídeo Relacionado com Gene de Calcitonina , Corticosterona/farmacologia , Dermatite , Modelos Animais de Doenças , Gânglios Espinais/metabolismo , Sistema Hipotálamo-Hipofisário/metabolismo , Masculino , Camundongos , Camundongos Transgênicos , Fator de Crescimento Neural , Neuropeptídeos , Sistema Hipófise-Suprarrenal/metabolismo , Psoríase/metabolismo , RNA Mensageiro , Receptores de Glucocorticoides/metabolismo , Estresse Psicológico/genética , Substância P , Ativação Transcricional , Regulação para Cima
6.
J Drugs Dermatol ; 12(9 Suppl): s123-7, 2013 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-24002160

RESUMO

Dyschromia is one of the most common dermatological concerns in patients with darker skin.1 Disorders of hyperpigmentation, including postinflammatory hyperpigmentation, melasma, solar lentigines, and miscellaneous causes of facial hyperpigmentation, are the most frequently treated dyschromias and can have a considerable psychosocial impact. Given the high prevalence of hyperpigmentation and the considerable demand for an even complexion, newer treatment options for hyperpigmentation are of growing interest among consumers, manufacturers, and dermatologists. Blinded, controlled studies demonstrating skin lightening effects in soy, niacinamide, n-acetylglucosamine, licorice extract, arbutin, vitamin c, kojic acid, emblica extract, lignin peroxidase, and glutathione have led to the development of a growing list of non-prescription skin care products that can be incorporated (mostly as adjuncts) in the management of hyperpigmentation.


Assuntos
Produtos Biológicos/química , Hiperpigmentação/tratamento farmacológico , Pigmentação da Pele , Produtos Biológicos/uso terapêutico , Fármacos Dermatológicos/química , Fármacos Dermatológicos/uso terapêutico , Humanos , Melanose/tratamento farmacológico , Medicamentos sem Prescrição/química , Medicamentos sem Prescrição/uso terapêutico , Higiene da Pele/métodos
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...